Cost-utility analysis of 177Lu-PSMA-617 radioligand therapy in second-line and third-line treatment for metastatic castration-resistant prostate cancer (mCRPC) in Germany
Although Germany lacks an explicit willingness-to-pay threshold for interpreting the ICER of Model I, it falls within the range of other reimbursed cancer therapies. This suggests PRLT is cost-effective as second- or third-line treatment for mCRPC. Between 2019 and 2022, hospitals mainly used self-produced <sup>177</sup>Lu-PSMA-617, which was less costly than the product now commercially available, limiting the generalizability of our findings.
Authors
- Tom Stargardt (ORCID: https://orcid.org/0000-0003-3954-0955)
- Richard P. Baum (ORCID: https://orcid.org/0000-0003-1723-0075)
- Carolin Brinkmann (ORCID: https://orcid.org/0000-0002-2550-0306)
Institutions
- Universität Hamburg (DE)
- Helios Dr. Horst Schmidt Kliniken Wiesbaden (DE)
- Deutsche Klinik für Diagnostik (DE)
- St. Josefs Hospital (DE)
- Hamburg Institut (Germany) (DE)
Publication Details
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2025-05-08
- DOI
- https://doi.org/10.1007/s00259-025-07317-9
- Citations
- 3
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 4.56
Funders
- Deutsche Forschungsgemeinschaft
- Universität Hamburg